M&A Deal Summary

ESSA Acquires Realm Therapeutics

On May 16, 2019, ESSA acquired life science company Realm Therapeutics for 22M USD

Acquisition Highlights
  • This is ESSA’s 1st transaction in the Life Science sector.
  • This is ESSA’s largest (disclosed) transaction.
  • This is ESSA’s 1st transaction in the United States.
  • This is ESSA’s 1st transaction in Pennsylvania.

M&A Deal Summary

Date 2019-05-16
Target Realm Therapeutics
Sector Life Science
Buyer(s) ESSA
Deal Type Add-on Acquisition
Deal Value 22M USD
Advisor(s) MTS Health Partners LP (Financial)
Cooley
Fasken Martineau DuMoulin (Legal)

Target

Realm Therapeutics

Malvern, Pennsylvania, United States
Realm Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel immunomodulatory therapies to protect and improve the lives of adults and children. Realm Therapeutics was founded in 2016 and is based in Malvern, Pennsylvania.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

ESSA

Vancouver, British Columbia, Canada

Category Company
Founded 2009
Sector Life Science
Employees25
DESCRIPTION

ESSA is a pharmaceutical company focused on developing novel and proprietary therapies for the treatment of castration-resistant prostate cancer ("CRPC") in patients whose disease is progressing despite treatment with current therapies. ESSA's proprietary "aniten" compounds bind to the N-terminal domain of the androgen receptor ("AR"), inhibiting AR-driven transcription and the AR signaling pathway in a unique manner which bypasses the drug resistance mechanisms associated with current anti-androgens. ESSA was founded in 2009 and is based in Vancouver, Canada.


DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (Pennsylvania) 1 of 1
Country (United States) 1 of 1
Year (2019) 1 of 1
Size (of disclosed) 1 of 1